GlassScriptPhysician profile
Melissa J Lueking
NPI 1043454812
$1,156.78
in general payments reported to CMS, 2019-2025
17 companies · $34.62 in 2025
The $34.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $17.33 · 2021: $371 · 2022: $99.05 · 2023: $238 · 2024: $241 · 2025: $34.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $172.04 | 2023-2025 | Synchromedii, Linq II, Inceptiv |
| Merck Sharp & Dohme LLC | $158.29 | 2019-2024 | Verquvo, Dificid, Zerbaxa |
| Abiomed | $138.84 | 2021 | |
| Gilead Sciences, INC. | $115.46 | 2021-2025 | |
| Pfizer INC. | $106.11 | 2019-2024 | |
| Cumberland Pharmaceuticals, INC. | $98.07 | 2019-2024 | Vibativ |
| Astrazeneca Pharmaceuticals LP | $66.98 | 2021-2024 | |
| Kestra Medical Technology Services, INC. | $48.07 | 2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $45.31 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $45.16 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $38.10 | 2020-2024 | Eliquis |
| Amgen INC. | $26.96 | 2019 | |
| Abbvie INC. | $25.84 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.83 | 2023 | Jardiance, Glyxambi |
| Mallinckrodt Hospital Products INC. | $17.02 | 2024 | Terlivaz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.31 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lueking listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.